## Rheumatoid Arthritis (RA)

## **Assessment and Classification of Disease Prognosis**

Physician Quality Reporting System	Data Collec	tion Sh	eet		
				/ / □ Male □ Female	
Patient's Name Practice Me	Practice Medical Record Number (MRN)			Birth Date (mm/dd/yyyy) Gender	
National Provider Identifier (NPI)				Date of Service	
Clinical Information				Billing Information	
Step 1 Is patient eligible for this measure?					
		Yes	No	Code Required on Claim Form	
Patient is aged 18 years and older on date	e of encounter.			Verify date of birth on claim form.	
Patient has a diagnosis of rheumatoid arthr	itis.			Refer to coding specifications document for list of applicable codes. Codes determining a patient's eligibility must be reported on the same claim as	
There is a CPT Code for this visit.					
If <b>No</b> is checked for any of the above, STOP. Do not report a CPT category II code.			the quality code(s) identified below.		
Step 2 Does patient meet the mea	asure?				
Disease Prognosis <sup>1</sup>		Yes	No	Code to be Reported on Line 24D of Paper Claim Form, if Yes (or Service Line 24 of Electronic Claim Form)	
Assessed, poor prognosis <sup>2</sup>				3475F	
Assessed, good prognosis				3476F	
				If <b>No</b> is checked for <b>all</b> of the above, report 3475F–8P (Disease prognosis for rheumatoid arthritis not assessed and classified, reason not otherwise specified.)	

<sup>2</sup>RA patients with features of poor prognosis have active disease with high tender and swollen joint counts, often have evidence of radiographic erosions, elevated levels of RF and or anti-CCP antibodies, and an elevated erythrocyte sedimentation rate, and an elevated C-reactive protein level.

<sup>&</sup>lt;sup>1</sup>Classification of disease prognosis should be based upon, at a minimum, the following clinical markers: functional limitation (eg, HAQ Disability Index), extraarticular disease (eg, vasculitis, Sjorgen's syndrome, RA lung disease, rheumatoid nodules), rheumatoid factor (RF) positivity, positive anti-cyclic citrullinated peptide (anti-CCP) antibodies (both characterized dichotomously, per CEP recommendation), and/or bony erosions by radiography.